Table 1.
RR of breast cancer and vitamin D in previous meta-analysis.
| Source | Type of vitamin D | Number of included studies | Type of included studies | RR (95%IC) |
|---|---|---|---|---|
| Bauer SR et al. (2013) | 25(OH)D | 9 | Cohort & nested case-control studies | 0.9 (0.97–1.00) |
| Chen P et al. (2010) | 25(OH)D | 21 | Case control, cohort, & cross-sectional studies | 0.55 (0.38–0.80) |
| Intake of vitamin D | 0.91 (0.85–0.97) | |||
| 1,25(OH)2D | 0.99 (0.68–1.44) | |||
| Chen P et al. (2013) | 25(OH)D | 21 | Nested case-control & retrospective studies | 0.86 (0.75–1.00) |
| Population based case control studies | 0.35 (0.24–0.52) | |||
| Hospital based case-control studies | 0.08 (0.08–0.33) | |||
| Gandini S et al. (2011) | 25(OH)D | 10 | Case-control | 0.83 (0.79–0.87) |
| Nested case-control & cohort studies | 0.97 (0.92–1.03) | |||
| Gissel T et al. (2008) | Intake of vitamin D | 6 | Cross sectional, Case-control, cohort & r&omized-control trials | 0.98 (0.93–1.03) |
| Kim Y and Je Y. (2014) | Intake of vitamin D | 24 | Cohort & nested case-control studies | 0.95 (0.88–1.01) |
| 25(OH)D | 0.92 (0.83–1.02) | |||
| Wang D et al. (2013) | 25(OH)D | 14 | Cohort & nested case-control studies | 0.84 (0.75–0.95) |
| Mohr SB et al. (2011) | 25(OH)D | 11 | All | 0.61 (0.47–0.80) |
| Case-control studies | 0.87 (0.77–0.99) | |||
| Nested case-control studies | 0.41 (0.31–0.56) | |||
| Yin L et al. (2010) | 25(OH)D | 9 | All | 0.73 (0.60–0.88) |
| Nested case-control | 0.92 (0.82–1.04) | |||
| Case- control | 0.59 (0.48–0.73) |